@article{0abe86526ad043378f699fe21d8e6e3d,
title = "How Can the Typhoid Fever Surveillance in Africa and the Severe Typhoid Fever in Africa Programs Contribute to the Introduction of Typhoid Conjugate Vaccines?",
abstract = "Background: The World Health Organization now recommends the use of typhoid conjugate vaccines (TCVs) in typhoid-endemic countries, and Gavi, the Vaccine Alliance, added TCVs into the portfolio of subsidized vaccines. Data from the Severe Typhoid Fever in Africa (SETA) program were used to contribute to TCV introduction decision-making processes, exemplified for Ghana and Madagascar. Methods: Data collected from both countries were evaluated, and barriers to and benefits of introduction scenarios are discussed. No standardized methodological framework was applied. Results: The Ghanaian healthcare system differs from its Malagasy counterpart: Ghana features a functioning insurance system, antimicrobials are available nationwide, and several sites in Ghana deploy blood culture-based typhoid diagnosis. A higher incidence of antimicrobial-resistant Salmonella Typhi is reported in Ghana, which has not been identified as an issue in Madagascar. The Malagasy people have a low expectation of provided healthcare and experience frequent unavailability of medicines, resulting in limited healthcare-seeking behavior and extended consequences of untreated disease. Conclusions: For Ghana, high typhoid fever incidence coupled with spatiotemporal heterogeneity was observed. A phased TCV introduction through an initial mass campaign in high-risk areas followed by inclusion into routine national immunizations prior to expansion to other areas of the country can be considered. For Madagascar, a national mass campaign followed by routine introduction would be the introduction scenario of choice as it would protect the population, reduce transmission, and prevent an often-deadly disease in a setting characterized by lack of access to healthcare infrastructure. New, easy-to-use diagnostic tools, potentially including environmental surveillance, should be explored and improved to facilitate identification of high-risk areas.",
keywords = "Ghana, Madagascar, Salmonella Typhi, mass campaign, typhoid fever, vaccine introduction",
author = "Jeon, {Hyon Jin} and Justin Im and Andrea Haselbeck and Marianne Holm and Rapha{\"e}l Rakotozandrindrainy and Bassiahi, {Abdramane Soura} and Ursula Panzner and Mogeni, {Ondari D.} and Seo, {Hye Jin} and Octavie Lunguya and Jan Jacobs and Okeke, {Iruka N.} and Mekonnen Terferi and Ellis Owusu-Dabo and Gordon Dougan and Megan Carey and Steele, {A. Duncan} and Kim, {Jerome H.} and Clemens, {John D.} and Andrews, {Jason R.} and Park, {Se Eun} and Stephen Baker and Florian Marks",
note = "Funding Information: Financial support. This research was funded by the Bill & Melinda Gates Foundation [OPP1127988]. The International Vaccine Institute acknowledges its donors including the Republic of Korea and the Swedish International Development Cooperation Agency. This publication was made possible through a grant from the Bill & Melinda Gates Foundation [OPP1201031]. Funding Information: Supplement sponsorship. This article was published as part of the supplement “Severe Typhoid Fever in Africa (SETA) Program” sponsored by the International Vaccine Institute. Funding Information: 1Department of Medicine, University of Cambridge, United Kingdom; 2International Vaccine Institute, Seoul, Republic of Korea; 3University of Antananarivo, Madagascar; 4Institut Sup{\'e}rieur des Sciences de la Population, Universit{\'e} Ouaga II, Ouagadougou, Burkina Faso; 5Institut National de Recherche Biom{\'e}dicale, Kinshasa, Democratic Republic of Congo; 6Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, and 7Department of Microbiology and Immunology, Katholieke Universiteit Leuven, Leuven, Belgium; 8Faculty of Pharmacy, University of Ibadan, Nigeria; 9Armauer Hansen Research Institute, ALERT Campus, Addis Ababa, Ethiopia; 10School of Public Health, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana; 11Bill & Melinda Gates Foundation, Seattle, Washington; 12icddr,b, Dhaka, Bangladesh; 13Fielding School of Public Health, University of California, Los Angeles; 14Korea University School of Medicine, Seoul; 15Stanford University, California; and 16Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam Publisher Copyright: {\textcopyright} 2019 The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.",
year = "2019",
month = oct,
day = "30",
doi = "10.1093/cid/ciz629",
language = "English",
volume = "69",
pages = "S417--S421",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
}